Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
1
20%
Ph phase_3
2
40%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Terminated(1)

Detailed Status

Recruiting3
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)

Trials by Status

not_yet_recruiting120%
recruiting360%
withdrawn120%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_3

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

NCT07262567
not_yet_recruitingphase_3

A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

NCT07668752
recruitingphase_1

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

NCT07259590
recruitingphase_1

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

NCT06500676
withdrawnphase_2

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

NCT07026916

Clinical Trials (5)

Showing 5 of 5 trials
NCT07262567Phase 3

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

Recruiting
NCT07668752Phase 3

A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

Not Yet Recruiting
NCT07259590Phase 1

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Recruiting
NCT06500676Phase 1

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Recruiting
NCT07026916Phase 2

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

Withdrawn

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5